About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Advisory Committee Backs Novartis’ SigniforR

by Kathy Jones on November 8, 2012 at 8:12 PM
Font : A-A+

 FDA Advisory Committee Backs Novartis’ SigniforR

An advisory committee for the US Food and Drug Administration has unanimously recommended that the health regulator approve Novartis' SigniforR drug for treating Cushing's disease patients who require medical therapeutic intervention.

FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) said that it has based its recommendation following the results of various studies, including PASPORT-CUSHINGS, which revealed that the drug rapidly reduced the mean urinary-free cortisol (UFC), the key measure of biochemical control of the disease.

Advertisement

The committee also acknowledged that the drug led to hyperglycemia and elevations in liver enzymes in the patients but said that lack of other therapies for treating the condition means that the benefits outweighed the side effects. "In spite of significant concerns about hyperglycemia and uncontrolled diabetes, I think it's very highly probable that those glucose levels can be adequately controlled with available medications for managing diabetes, including insulin", Brown University's Robert Smith, who was part of the panel, said.


Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Turmeric Powder - Health Benefits, Uses & Side Effects Iron Intake Calculator Post-Nasal Drip Diaphragmatic Hernia A-Z Drug Brands in India Noscaphene (Noscapine) Find a Hospital Selfie Addiction Calculator Loram (2 mg) (Lorazepam) Accident and Trauma Care
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use